Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.)

中文翻译：

---

人群药代动力学和药效学分析，以评估在HIV-1感染者中切换至Doravirine / Lamivudine /替诺福韦富马酸替诺福韦酯。

Doravirine是一种非核苷类逆转录酶抑制剂，可用于治疗1型人类免疫缺陷病毒（HIV-1）感染。针对doravirine临床研究中未接受过治疗的参与者的群体药代动力学（PK）模型，使用DRIVE-SHIFT试验中转换参与者的数据进行了更新，并用于估计个体事后PK参数值并评估疗效的暴露-反应关系。该结果支持100 mg艾滋病毒感染者转用基于Doravirine的治疗方案的剂量（该研究已在ClinicalTrials.gov上进行注册，临床注册号为NCT02397096。）